Objectives: Nucleophosmin (NPM) is a nucleolar phosphoprotein which plays role in ribosome biogenesis and centrosome duplication. Changes in NPM expression has been reported in various malignancies. In 2008 WHO classification for acute myeloid leukemias (AML), a provisional subgroup harboring NPM mutation, which leads to its cytoplasmic localization, has been introduced. P27 is a CDK inhibitor which is disabled in various malignancies. Cytoplasmic NPM1 (cNPM1) and P27 expression in AML cases and their relation with survival and other clinical/laboratory findings, have been investigated in this study. Methods: Thirty, histologically confirmed, AML cases that had underwent bone marrow biopsy (BMB) between 2010 to 2013 in Quaem university hospital, participated the study. cNPM1 and P27 expressions were evaluated using IHC staining on BMB samples. The clinical and laboratory as well as survival data were extracted from hospital data or through contact with patients. Results: cNPM1 and P27 expression rates were 29% and 23%, respectively. There was a significant relation between cNPM1 expression as well as P27 expression and high (>10000/µl) WBC count (P=0.010 and P= 0.033, respectively). There were no significant differences between survival of patients with cNPM1 or P27 expression and the other patients. Conclusions: cNPM1 and P27 expressions may be associated with higher WBC count in AML. Their expressions were not associated with survival in this study. Further studies with larger sample size as well as concurrent investigation of other genetic abnormalities are needed to clarify the exact prognostic impact of these markers in AML.
